{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:25:36Z","timestamp":1761128736500},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,7,1]]},"DOI":"10.1097\/qai.0b013e31817af47a","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T18:39:52Z","timestamp":1236278392000},"page":"304-309","source":"Crossref","is-referenced-by-count":39,"title":["A Phase 2, Open-Label Study of the Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis"],"prefix":"10.1097","volume":"48","author":[{"given":"Jos\u00e9 A","family":"Vazquez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A","family":"Schranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth P","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Reboli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Fichtenbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-10-20210131","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/CMR.11.2.382","article-title":"Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.","volume":"11","author":"White","year":"1998","journal-title":"Clin Microbiol Rev"},{"key":"R2-10-20210131","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1086\/313765","article-title":"Refractory mucosal candidiasis in advanced human immunodeficiency virus infection.","volume":"30","author":"Fichtenbaum","year":"2000","journal-title":"Clin Infect Dis"},{"key":"R3-10-20210131","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1592\/phco.19.1.76.30509","article-title":"Options for the management of mucosal candidiasis in patients with AIDS and HIV infection.","volume":"19","author":"Vazquez","year":"1999","journal-title":"Pharmacotherapy"},{"key":"R4-10-20210131","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00126334-200210010-00009","article-title":"Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole.","volume":"31","author":"Kartsonis","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R5-10-20210131","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s100960000323","article-title":"Determinants for the development of oropharyngeal colonization or infection by fluconazole-resistant Candida strains in HIV-infected patients.","volume":"19","author":"Masia Canuto","year":"2000","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R6-10-20210131","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/infdis\/173.1.219","article-title":"Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients.","volume":"173","author":"Maenza","year":"1996","journal-title":"J Infect Dis"},{"key":"R7-10-20210131","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/infdis\/174.4.821","article-title":"Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients.","volume":"174","author":"Revankar","year":"1996","journal-title":"J Infect Dis"},{"key":"R8-10-20210131","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1086\/317936","article-title":"HIV Epidemiology Research Study (HERS) Group. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women.","volume":"183","author":"Sobel","year":"2001","journal-title":"J Infect Dis"},{"key":"R9-10-20210131","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1128\/AAC.44.3.747-751.2000","article-title":"Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998.","volume":"44","author":"Pfaller","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-10-20210131","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/00002030-200005050-00011","article-title":"Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection. Adult AIDS Clinical Trials Group Study Team 295.","volume":"14","author":"Fichtenbaum","year":"2000","journal-title":"AIDS"},{"key":"R11-10-20210131","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/jac\/dkh179","article-title":"Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study.","volume":"53","author":"Kartsonis","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"R13-10-20210131","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1086\/322641","article-title":"Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis.","volume":"33","author":"Vazquez","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R14-10-20210131","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1128\/AAC.46.6.1704-1713.2002","article-title":"Resistance mechanisms in clinical isolates of Candida albicans.","volume":"46","author":"White","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R15-10-20210131","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/jac\/46.2.338","article-title":"Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidiasis.","volume":"46","author":"Muller","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"R16-10-20210131","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1146\/annurev.mi.48.100194.002351","article-title":"Antibiotics that inhibit fungal cell wall development.","volume":"48","author":"Debono","year":"1994","journal-title":"Annu Rev Microbiol"},{"key":"R17-10-20210131","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1469-0691.2001.00158.x","article-title":"In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species.","volume":"7","author":"Moore","year":"2001","journal-title":"Clin Microbiol Infect"},{"key":"R18-10-20210131","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1128\/AAC.47.10.3149-3154.2003","article-title":"Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.","volume":"47","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"R19-10-20210131","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/jac\/dkh504","article-title":"Initial results from a longitudinal international surveillance programme for anidulafungin (2003).","volume":"54","author":"Messer","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"R20-10-20210131","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1128\/AAC.48.6.2021-2024.2004","article-title":"Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia.","volume":"48","author":"Krause","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-10-20210131","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/423378","article-title":"A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.","volume":"39","author":"Krause","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R22-10-20210131","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1177\/0091270004265644","article-title":"Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal.","volume":"44","author":"Dowell","year":"2004","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 1","key":"R23-10-20210131","first-page":"290","article-title":"Anidulafungin dosage adjustments are not required for patients with hepatic and\/or renal impairment.","volume":"9","author":"Dowell","year":"2003","journal-title":"Clin Microbiol Infect"},{"key":"R25-10-20210131","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/0016-5085(94)90122-8","article-title":"The natural history of esophageal candidiasis after successful treatment in patients with AIDS.","volume":"107","author":"Laine","year":"1994","journal-title":"Gastroenterology"},{"key":"R26-10-20210131","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1310\/T7A7-1E63-2KA0-JKWD","article-title":"Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIV\/AIDS patients.","volume":"1","author":"Vazquez","year":"2000","journal-title":"HIV Clin Trials"},{"key":"R27-10-20210131","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1086\/514571","article-title":"Refractory mucosal candidiasis in patients with human immunodeficiency virus infection.","volume":"26","author":"Fichtenbaum","year":"1998","journal-title":"Clin Infect Dis"},{"key":"R28-10-20210131","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1097\/00002030-199610000-00009","article-title":"Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal long-term continuous versus intermittent fluconazole therapy.","volume":"10","author":"Phillips","year":"1996","journal-title":"AIDS"},{"key":"R29-10-20210131","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1128\/AAC.49.2.767-769.2005","article-title":"Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis.","volume":"49","author":"Moudgal","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R31-10-20210131","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1128\/AAC.48.4.1382-1383.2004","article-title":"Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis.","volume":"48","author":"Hernandez","year":"2004","journal-title":"Antimicrob Agents Chemother"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00126334-200807010-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T07:22:27Z","timestamp":1618039347000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-200807010-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,1]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e31817af47a","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7,1]]}}}